Stock Analysis

Assessing TransMedics Group And Two Other Stocks That Might Be Trading Below Estimated Value

NasdaqGM:TMDX
Source: Shutterstock

As the U.S. market navigates a landscape marked by fluctuating indices and rising Treasury yields, investors are closely watching legislative developments that could impact economic conditions. Amidst this environment, identifying stocks that may be trading below their estimated value can offer potential opportunities for those looking to capitalize on market inefficiencies.

Advertisement

Top 10 Undervalued Stocks Based On Cash Flows In The United States

NameCurrent PriceFair Value (Est)Discount (Est)
Berkshire Hills Bancorp (NYSE:BHLB)$26.27$51.5449%
Quaker Chemical (NYSE:KWR)$107.26$210.0648.9%
Super Group (SGHC) (NYSE:SGHC)$8.44$16.5449%
KBR (NYSE:KBR)$55.33$108.4049%
Horizon Bancorp (NasdaqGS:HBNC)$15.69$30.6848.9%
Insteel Industries (NYSE:IIIN)$36.65$72.2349.3%
First Reliance Bancshares (OTCPK:FSRL)$9.45$18.4948.9%
Carvana (NYSE:CVNA)$302.29$586.8948.5%
Verra Mobility (NasdaqCM:VRRM)$24.53$47.9148.8%
Mobileye Global (NasdaqGS:MBLY)$16.05$31.0748.3%

Click here to see the full list of 171 stocks from our Undervalued US Stocks Based On Cash Flows screener.

Here's a peek at a few of the choices from the screener.

TransMedics Group (NasdaqGM:TMDX)

Overview: TransMedics Group, Inc. is a commercial-stage medical technology company focused on transforming organ transplant therapy for end-stage organ failure patients globally, with a market cap of $4.13 billion.

Operations: The company's revenue is primarily derived from its Surgical & Medical Equipment segment, which generated $488.23 million.

Estimated Discount To Fair Value: 47.9%

TransMedics Group is trading at US$124.71, significantly below its estimated fair value of US$239.19, suggesting it may be undervalued based on cash flows. Recent earnings showed strong growth with Q1 2025 revenue at US$143.54 million and net income of US$25.68 million, reflecting improved profitability. The company's revised full-year revenue guidance projects up to $585 million, indicating robust future growth potential despite debt concerns not fully covered by operating cash flow.

NasdaqGM:TMDX Discounted Cash Flow as at May 2025
NasdaqGM:TMDX Discounted Cash Flow as at May 2025

Willdan Group (NasdaqGM:WLDN)

Overview: Willdan Group, Inc. offers professional, technical, and consulting services mainly in the United States and has a market cap of $731.80 million.

Operations: The company's revenue is derived from two main segments: Energy, contributing $498.81 million, and Engineering & Consulting, accounting for $96.88 million.

Estimated Discount To Fair Value: 14.9%

Willdan Group, trading at US$50.55, is undervalued based on cash flows with an estimated fair value of US$59.43. Earnings are expected to grow significantly at 23.4% annually, outpacing the broader US market. Recent Q1 2025 results showed a revenue increase to US$152.39 million and net income of US$4.69 million, reflecting ongoing profitability improvements amid strategic acquisitions and expanded credit facilities enhancing financial flexibility for future growth initiatives.

NasdaqGM:WLDN Discounted Cash Flow as at May 2025
NasdaqGM:WLDN Discounted Cash Flow as at May 2025

Grindr (NYSE:GRND)

Overview: Grindr Inc. operates a social networking and dating application catering to the LGBTQ community globally, with a market cap of $4.66 billion.

Operations: The company's revenue primarily comes from its Internet Information Providers segment, generating $363.23 million.

Estimated Discount To Fair Value: 31.4%

Grindr, trading at US$24.31, is significantly undervalued with a fair value estimate of US$35.45. The company reported Q1 2025 sales of US$93.94 million and net income of US$27.02 million, reversing a previous loss, alongside raised full-year revenue growth guidance to 26% or more. Despite insider selling and profitability expected within three years, Grindr's strategic expansions and share buyback program underscore its potential for enhanced cash flow valuation.

NYSE:GRND Discounted Cash Flow as at May 2025
NYSE:GRND Discounted Cash Flow as at May 2025

Make It Happen

Searching for a Fresh Perspective?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Valuation is complex, but we're here to simplify it.

Discover if TransMedics Group might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NasdaqGM:TMDX

TransMedics Group

A commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.

High growth potential and slightly overvalued.

Advertisement